Overview of Duspatalin Retard

Duspatalin Retard is a specialized, single-ingredient pharmaceutical preparation designed for oral administration, primarily functioning to relieve painful muscle spasms in the digestive tract. It is classified as a targeted musculotropic antispasmodic drug.

Property	Description
Active ingredient	Mebeverine hydrochloride
Form	Prolonged-release hard capsules
Pharmacological class	Musculotropic Antispasmodic (Spasmolytic)
General purpose	To ease intestinal muscle spasms and tension
Origin	Synthetic organic compound

What is the Pharmacological Class of Duspatalin Retard?

The medicine belongs to the musculotropic antispasmodic class, meaning its primary action is a direct smooth muscle relaxant effect on the smooth muscle cells lining the gastrointestinal tract. The active substance, mebeverine hydrochloride, is a synthetic organic compound specifically engineered to alleviate the intense tightening and cramping of the intestinal walls. The efficacy of mebeverine in managing symptoms related to intestinal functional disorders ensures that patients receive relief focused directly on the source of the physical discomfort. This class of medicine is clinically recognized for providing localized relief to the gut.

Composition and Meaning of the ‘Retard’ Designation

Duspatalin Retard contains mebeverine as its single active ingredient. The trade name 'Retard' is an intrinsic characteristic of the dosage form, signifying that the medicine is manufactured as a prolonged-release or modified-release hard gelatin capsule. This specialized oral delivery system is regulated to ensure the active substance maintains a steady, therapeutic level over an extended period. This controlled delivery is essential for providing sustained relief from smooth muscle contractions throughout the day, often simplifying the regimen compared to immediate-release forms.

What is the General Purpose of this Antispasmodic?

The general purpose of this medicine is to address the underlying physical discomfort caused by irregular and excessive intestinal muscle activity. By selectively acting as a spasmolytic, Duspatalin Retard helps to normalize the contractile activity within the digestive tract, thereby easing the abdominal tension and painful spasms. A typical neutral use scenario involves managing recurring periods of gut cramping and discomfort, demonstrating the drug's role in restoring normal intestinal muscle function.

Regulatory References

What side effects are possible with Duspatalin Retard?

Possible Side Effects and Safety Information

The safety profile of Duspatalin Retard (mebeverine hydrochloride) is defined by officially documented adverse effects and necessary restrictions, as classified by government regulatory agencies. The primary safety concerns reported involve hypersensitivity (allergic) reactions that affect the immune system and the skin.

Officially Documented Adverse Reactions

Adverse reactions are predominantly classified by regulators as 'Not known' (frequency cannot be estimated from available post-marketing data). The reported effects belong to the following System-Organ Classes:

System-Organ Class	Example Manifestations
Immune System Disorders	Hypersensitivity reactions, Anaphylactic reactions
Skin and Subcutaneous Tissue Disorders	Urticaria (hives), Rash, Face oedema, Angioedema

Serious Reactions and Safety Constraints

The official label documents that serious adverse reactions, which are manifestations of severe allergic response, may include Angioedema (serious swelling of the face, lips, tongue, or throat) and Anaphylactic Reactions.

Safety restrictions establish that the medicine is strictly contraindicated and should not be used in individuals with a known hypersensitivity to mebeverine hydrochloride or to any of the inactive ingredients (excipients).

Population-Specific Safety Considerations

The use of mebeverine is not recommended in certain populations due to limited or insufficient data in official safety documents:

Pregnancy and Breastfeeding: Not recommended for use during pregnancy or while breastfeeding.
Children and Adolescents: Not recommended for those under 18 years of age.

No specific safety adjustments are mandated in regulatory labels for older adults or individuals with renal or hepatic impairment, based on available data.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Mebeverine hydrochloride (the active substance in Duspatalin Retard) describes overdose scenarios primarily based on reported cases where symptoms were typically absent or mild and rapidly reversible.

Feature	Official Regulatory Statement
Documented Manifestations	Observed symptoms in overdosage have included those of a neurological nature and a cardiovascular nature.
CNS Over-exposure	Central Nervous System (CNS) excitability may theoretically occur in cases of massive or acute overdosage.
Special Populations	The regulatory profile notes that no specific overdose risk has been identified for elderly, renal, or hepatic impaired patients from available post-marketing data regarding the usual recommended dose.

Immediate Action Mandates

In the event of a suspected overdose, it is mandated by regulatory authorities that an individual seek medical attention immediately. Patients are instructed to consult a doctor or go to a hospital straight away, even if symptoms appear mild or absent.

Overdose Management

No specific antidote is known for Mebeverine overdosage. Management is therefore limited to symptomatic and supportive treatment. Procedural steps, such as gastric lavage, are only considered by healthcare professionals in specific circumstances, such as shortly after the ingestion of a massive dose or in cases of multiple intoxication.

Therapeutic Uses of Duspatalin Retard

Quick Facts: Therapeutic Areas

Irritable Bowel Syndrome (IBS): Helps manage the collection of symptoms associated with this common gastrointestinal condition.
Abdominal Discomfort: Used for the symptomatic relief of pain and cramping in the abdominal region.
Bowel Irregularities: Supports the mitigation of certain bowel function disturbances, including related instances of diarrhea or constipation.

Duspatalin Retard is a therapeutic option indicated for the symptomatic management of Irritable Bowel Syndrome (IBS). It is utilized to address a range of uncomfortable, recurring gastrointestinal issues that define the condition.

This medication is primarily purposed to assist in the relief of abdominal pain and cramping. It provides support for managing the discomfort and the spasms that can occur within the intestines. Furthermore, it contributes to easing other common associated symptoms, such as bloating and excessive flatulence.

By helping to relieve gastrointestinal spasms, the medication can also support the normalization of bowel function, which is often irregular in individuals with IBS, affecting both diarrhea- and constipation-predominant patterns. The overall goal is to provide reliable symptom control as part of a comprehensive management strategy for the condition. It is established for use in adults and adolescents to promote general intestinal comfort.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility profile for Duspatalin Retard (mebeverine hydrochloride prolonged-release capsules) is strictly defined by government regulatory documents, determining which populations are permitted or restricted from using the medicine.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults, including the elderly.
Populations for whom use is contraindicated	Patients with known hypersensitivity to mebeverine hydrochloride or to any of the excipients.
Age-related eligibility rules	Adults are permitted; Pediatric use is not recommended in those below 18 years due to insufficient data on efficacy and safety for the prolonged-release formulation.
Condition-specific eligibility rules	No dosage adjustment is deemed necessary for older adults or patients with existing renal or hepatic impairment.
Pregnancy and lactation eligibility status	Pregnancy: Not recommended (limited human data). Lactation: Should not be used (unknown if excreted in human milk).
Eligibility-related restrictions	Contraindicated in patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption (due to excipients like lactose/sucrose).

The regulatory profile formally defines the permitted user base as adults and requires exclusion for specific groups, primarily those with a history of hypersensitivity or certain hereditary metabolic disorders, which are classified as contraindications. Use in the pediatric population (below 18), during pregnancy, and during lactation is formally not recommended due to a lack of sufficient established safety data, as explicitly stated in the regulatory label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for mebeverine hydrochloride, the active ingredient in Duspatalin Retard, establishes a specific interaction profile that is defined primarily by the absence of established drug-drug interactions.

Documented Interaction Profile

Interaction Type	Official Regulatory Statement
Drug-Drug Interactions (DDI)	Regulatory documents state that no formal drug-drug interaction studies have been performed. No specific medicinal products are documented as interacting.
Metabolic Mechanisms	No formal studies assessing effects via CYP enzymes or other metabolic pathways have been conducted, meaning no specific metabolic interactions are documented.
Exposure Modification	No substances are documented to increase, decrease, or otherwise alter drug levels (AUC or C max) of mebeverine.
Timing Requirements	No mandatory rules for separation of administration with other medicines are documented in official labeling.
Contraindicated Combinations	No medicinal products are formally designated as contraindicated for co-administration due as a result of interaction risk.

Interaction with Alcohol

The only substance for which formal interaction data is explicitly mentioned in regulatory labels is ethanol (alcohol). Studies demonstrate the absence of any interaction between mebeverine hydrochloride and ethanol. This finding confirms that co-administration does not result in a pharmacokinetic or pharmacodynamic interaction that alters the regulatory profile of either substance. Furthermore, official labeling does not document any required restrictions concerning food, herbal products, or supplements.

Mechanism of Action

How Duspatalin Retard Works — Mechanism of Action

Direct Blockade of Smooth Muscle Calcium Channels

Mebeverine, the active ingredient, acts as a non-specific spasmolytic by directly inhibiting voltage-dependent L-type calcium channels on the membrane of gastrointestinal smooth muscle cells. This action interrupts the crucial influx of Ca^2+ ions, leading to the molecular cascade that results in the induction of muscle relaxation.

Selective Modulation of Muscle Contraction Pathways

By limiting the Ca^2+ availability inside the cell, the drug prevents the activation of myosin light-chain kinase (MLCK), which is essential for the muscle's contractile apparatus. This targeted interference selectively modulates pathological hyperspastic contractions without causing general intestinal atony (paralysis), which results in the modulation of intestinal contraction patterns.

Physiological Outcome: Change in Muscle Tone

The overall mechanism induces the modulation of overactive gastrointestinal smooth muscle tone, resulting in diminished frequency and intensity of excessive smooth muscle contractions in the bowel wall. The subsequent muscle relaxation alters the mechanical tension within the GI tract wall, which influences afferent neuronal signaling.

Dosage and Administration Information

The administration of Duspatalin Retard is structured to optimize the function of its prolonged-release formulation. The medicine is intended for oral use as 200 mg hard capsules of mebeverine hydrochloride. The standardized regimen for adults is one capsule (200 mg) taken twice daily, administered once in the morning and once in the evening, resulting in a total standard daily dose of 400 mg.

Official Administration Protocol

The method of administration is crucial to the drug's function. The capsule must be swallowed whole with a sufficient amount of water, typically at least 100 ml. It is an explicit instruction that the capsule must not be chewed or crushed under any circumstances, as damaging the coating compromises the modified-release mechanism and the controlled delivery of the active substance over a twelve-hour period. While meal timing may vary, some information suggests administration approximately 20 minutes before a meal.

In terms of duration, the medicine's use is not limited, and the dosage may be gradually reduced after several weeks if sufficient relief is maintained. If a dose is missed, the next scheduled dose should be taken and no double dose should be taken to compensate.

Population-Specific Rules

No dosage adjustment is necessary for older patients or those with pre-existing renal or hepatic impairment. However, mebeverine prolonged-release capsules are not recommended for use in children and adolescents below 18 years due to insufficient data on efficacy and safety in this age group.

Recent Clinical Evidence

Duspatalin Retard: Recent Clinical Evidence

This section summarizes the published research regarding mebeverine (the single active ingredient in Duspatalin Retard), focusing on what has been studied and what remains uncertain, based on systematic reviews and clinical trial summaries.

Evidence for use in Irritable Bowel Syndrome (IBS)

Research on the active ingredient, mebeverine, has been conducted in adults with Irritable Bowel Syndrome, which is a condition characterized by fluctuating or episodic manifestations. Research has extensively examined the drug through Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies primarily monitored patient-reported outcomes describing perceived discomfort, such as the frequency and intensity of outcomes related to physical discomfort (abdominal pain) and the overall global assessment of symptom status.

Findings from this research describe patterns observed in the studies, including measurements related to abdominal pain. However, when looking at the overall improvement of all IBS symptoms combined, findings were mixed across various systematic reviews. This inconsistency in results contributes to the broader evidence landscape.

Evidence for use in Other Functional Bowel Disorders

Studies have explored the use of mebeverine in conditions beyond Irritable Bowel Syndrome that are also marked by functional limitations and painful outcomes capturing phases of heightened symptom activity. The evidence for these uses often comes from older or smaller controlled trials and observational settings evaluating daily-life functioning, where research examined how symptoms evolved in the observed populations against active comparators or open-label observation. The evidence base for these uses is characterized by smaller-scale studies compared to IBS, and data for the prolonged-release formulation specifically in these other functional conditions remain limited.

Long-term Studies and Follow-up

Most controlled clinical trials observing responses over defined time intervals have been conducted over short-term periods, typically ranging up to 16 weeks (four months). This duration was studied for assessing the initial symptomatic change. Consequently, there is limited information for long-term outcomes regarding the sustained effects of the medicine. Research has not fully established whether the reported symptom patterns continue indefinitely.

Evidence in Special Populations

Data for certain groups remain insufficient. For instance, dedicated, high-powered controlled research in older adults is limited. Furthermore, research examined the use of mebeverine in adolescents with IBS or functional abdominal pain, and findings indicated that the patient-reported outcomes describing perceived discomfort was observed in some studies to be similar between the mebeverine group and the placebo group.

What is Still Uncertain About Duspatalin Retard Research

The evidence quality varies across studies due to methodological differences, leading to findings were mixed and is referred to by researchers as heterogeneity (inconsistency). One of the primary research limitation frames is that follow-up durations were limited across many key trials, meaning the long-term effects of the medicine are not fully established. Also, research explores the role of the medicine across all specific subtypes of IBS, as subgroup findings are uncertain.

Key Studies & References

A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome (Supports mixed findings, heterogeneity, and adult IBS trial outcomes)

Frequently Asked Questions (FAQ)

Common questions about Duspatalin Retard (FAQ)

Q: How quickly should I expect Duspatalin Retard to start working?

According to official patient information, the onset of action for this medicine is generally noticed within about one hour. Symptom improvement is generally described as being noticeable within 1 to 3 hours after administration.

Q: Does Duspatalin Retard help with abdominal pain?

Official labeling states that the medicine is used for the management of symptoms, including abdominal pain and cramps, by acting to ease muscle spasms in the digestive tract.

Q: Can Duspatalin Retard be taken long-term?

Official regulatory guidelines indicate that the duration of use for this medicine is not limited. The duration of treatment is determined by a healthcare professional.

Q: Does Duspatalin Retard cause constipation or diarrhea?

Constipation and diarrhea are listed among the symptoms the medicine is intended to treat, as it helps modulate intestinal function. Official safety documents do not commonly list them as adverse effects caused by the medication itself.

Q: Can Duspatalin Retard affect my blood pressure?

Regulatory documents mention a drop in blood pressure as a potential sign of a rare, severe allergic reaction (anaphylaxis). Some other rare cardiovascular effects like palpitations (an unusual heart rhythm awareness) have also been reported.

Q: What happens if I forget to take a dose of Duspatalin Retard?

Official regulatory documents specify that if a dose is missed, the patient proceeds with the next scheduled dose and should not take a double dose to compensate for the forgotten capsule.

Q: Does Duspatalin Retard interact with oral contraceptives (birth control pills)?

Official regulatory documents state that no interactions with other medicines are known. Patient guidance further confirms that mebeverine does not affect oral contraceptives or other forms of hormonal birth control.

Q: Can Duspatalin Retard be used by people with glaucoma?

Mebeverine is a musculotropic antispasmodic. Unlike certain other drug classes, glaucoma is not listed as a specific contraindication in official regulatory documents.

Q: Does Duspatalin Retard interact with medicines for acid reflux?

According to official product information, no specific medicinal products are documented as interacting with mebeverine. This includes general medicines used for acid reflux.

Q: Why is Duspatalin Retard often prescribed for IBS?

It is often prescribed because it is a musculotropic antispasmodic designed to target the cause of discomfort. The medicine is designed to relax the smooth muscles of the intestine to address the painful cramps and spasms often associated with Irritable Bowel Syndrome (IBS).

Q: Are there any known food interactions with Duspatalin Retard?

Official labeling documents that no required restrictions concerning food are necessary. Generally, patients can eat and drink normally while taking the medicine.

Q: Is it safe to drive after taking Duspatalin Retard?

Official patient information addresses this question directly, indicating that it is unlikely that this medicine will affect the ability to drive or use machines.

Q: Are there any reported cases of Duspatalin Retard causing weight changes?

Official patient information explicitly states that mebeverine does not cause weight gain or weight loss.

Q: Does Duspatalin Retard have a sedative effect?

Patient-facing information indicates that side effects like tiredness or drowsiness are very rarely reported. It is not generally associated with a sedative effect.

Q: What does the research say about Duspatalin Retard's effectiveness for bloating?

Official patient information and labeling list bloating and gas among the symptoms that the medicine is used for in the management of functional bowel disorders.

Q: Is it normal to feel slightly dizzy after taking Duspatalin Retard?

Dizziness or light-headedness can occur in some individuals, as reported in the official safety information. This is a documented potential effect.

Q: Is there a maximum time someone can stay on Duspatalin Retard?

Official regulatory guidelines state that the duration of use for this medicine is not limited. Any adjustments to the duration of treatment are determined by a healthcare professional.

Q: How does Duspatalin Retard target the gut specifically?

It targets the gut by having a direct smooth muscle relaxant effect on the gastrointestinal tract. This action is selective, meaning it does not generally affect the normal movement (motility) of the gut.

Q: What are the signs of a severe allergic reaction to Duspatalin Retard?

Signs of a severe allergic reaction (hypersensitivity) may include difficulty breathing or swelling of the face, neck, lips, tongue, or throat, as described in patient information. These manifestations are documented in patient information as signs of a severe allergic reaction.

Q: Does Duspatalin Retard work for stomach cramps or only intestinal spasms?

Official labeling states that the medicine is used for the treatment of abdominal pain and cramps and acts on the smooth muscle of the entire gastrointestinal tract, which includes the intestines and stomach.

Q: Can Duspatalin Retard interact with herbal supplements?

Official labeling does not document any required restrictions concerning the co-administration of herbal products or supplements with this medicine.

Q: Is Duspatalin Retard chemically similar to other spasm-relieving drugs?

It belongs to the pharmacological group of musculotropic antispasmodics (or spasmolytics). Technically, it is chemically classified as a synthetic anticholinergic (an ester with a tertiary amino group).

Q: What is the half-life of mebeverine in the body, generally speaking?

The active substance is quickly metabolized by the body. Official regulatory documents report that the elimination half-life of the main metabolite (DMAC) in the blood is approximately 5.77 hours for the prolonged-release capsule.

Q: Does Duspatalin Retard change how food moves through the digestive system?

Official information states that the medicine acts on the smooth muscle of the gastrointestinal tract without affecting the normal movement (motility) of the gut. Its action is focused on relaxing spasms.

Q: Can Duspatalin Retard be taken on an empty stomach?

Official product information suggests administering the capsule approximately 20 minutes before a meal with a sufficient amount of water. This specific timing is suggested in the product information.

How should Duspatalin Retard be stored and disposed of?

Storage Conditions

Duspatalin Retard capsules must be stored according to regulatory requirements to ensure product stability. The medicine should be stored at a temperature below 25°C (or 30 C depending on the label) and must not be frozen. It is mandatory to keep the product in the original packaging, in a dry place, and protected from light. For safety, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Duspatalin Retard must comply with local guidelines for pharmaceutical waste. The medicine must not be disposed of by flushing it down the toilet or throwing it into household waste. Consult a pharmacist for instructions on how to properly discard the product to protect the environment.

Duspatalin Retard